Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally defined leukemia stem cells, while sparing normal stem and progenitor cells. In addition to efficacy as single agents, flavaglines sensitize leukemia cells to several anticancer compounds, including front-line chemotherapeutic drugs used to treat leukemia patients. Mechanistic studies indicate that flavaglines strongly inhibit protein synthesis, leading to the reduction of short-lived antiapoptotic proteins. Notably though, treatment with flavaglines, alone or in combination with other drugs, yields a much stronger cytotoxic activity toward leukemia cells than the translational inhibitor temsirolimus. These results indicate that the underlying cell death mechanism of flavaglines is more complex than simply inhibiting general protein translation. Global gene expression profiling and cell biological assays identified Myc inhibition and the disruption of mitochondrial integrity to be features of flavaglines, which we propose contribute to their efficacy in targeting leukemia cells. Taken together, these findings indicate that rocaglamide and silvestrol are distinct from clinically available translational inhibitors and represent promising candidates for the treatment of leukemia.
INTRODUCTION
In the past decade, a relatively new focus in drug development has been the concept of a cancer stem cell, where the diversity within tumors arises at least in part as a consequence of developmental programs that mirror normal tissue systems. 1 Perhaps, the best characterized cancer stem cells are those found in the blood cancer acute myelogenous leukemia (AML). Several studies have identified malignant stem cells, termed leukemia stem cells (LSCs) , that are central to the initiation, growth and relapse of AML. 2, 3 The high rates of relapse in AML patients suggest that current chemotherapeutic strategies do not adequately target LSCs. Thus, there is great interest in the development/identification of compounds that target LSCs, but still maintain an optimal therapeutic index.
Nearly half of the agents used in cancer therapy today are either natural products or derivatives of natural products. 4 A group of flavagline compounds from the plant genus Aglaia have attracted attention owing to their insecticidal activities and inhibition of tumor growth. 5 Two members of this family, rocaglamide and silvestrol, have shown toxicity toward leukemia cells. [6] [7] [8] [9] The Li-Weber group has shown that rocaglamide induces apoptosis in malignant but not normal proliferating lymphocytes, possibly attributed to its ability to suppress selectively mitogen-activated protein kinase/extracellular signal-regulated kinase survival activity in the cancer. 6, 8 Silvestrol has shown efficacy in vitro and in mouse models of the B-cell malignancies, chronic lymphocytic leukemia, acute lymphoblastic leukemia and mantle cell lymphoma, at doses that caused no discernable toxicity. In these studies, the activity of silvestrol was due at least in part to loss of the antiapoptotic protein Mcl-1, with subsequent mitochondrial depolarization and caspase-dependent apoptosis. 7, 10 In addition to leukemia, silvestrol has shown activity toward lung, breast and prostate cancer cells, and thus the utility of these compounds may extend beyond hematologic malignancies. 11, 12 Studies have shown that silvestrol promotes an aberrant interaction between capped mRNA and eIF4A, thereby interfering with the assembly of the eIF4F translation complex and blocking translation initiation. 13, 14 Consistent with these observations, recent work has identified eIF4A as one of the primary targets of rocaglamide and silvestrol. 15 Hence, the activity of these compounds appears to be related to their ability to inhibit translation. Extensive in vitro evidence now points to the translational machinery as a powerful therapeutic target in cancer, including hematologic malignancies. 16, 17 The translation initiation complex constitutes a major node of convergence for numerous signaling pathways; however, few agents impact this machinery directly, leaving this avenue largely unexplored in vivo. Thus, flavaglines are a unique set of compounds that represent the first direct inhibitor of translation initiation with clinical potential, as evidenced by their preclinical activity on an array of tumor types in the nanomolar range.
Here we show that rocaglamide and silvestrol preferentially kill phenotypically and functionally defined LSCs, while sparing normal stem and progenitor cells. Importantly, these compounds are significantly more toxic to leukemia cells as single agents or in combination with other anticancer drugs than clinically available translational inhibitors. This difference in cytotoxicity, however, is not attributable to the respective differences after inhibition of global protein synthesis; rather, it appears that they more efficiently decrease levels of Myc protein and also alter mitochondrial integrity via p53 activation.
MATERIALS AND METHODS

Primary AML and normal hematopoietic cells
Normal and leukemic human bone marrow samples were obtained after informed consent from volunteer donors at the University of Rochester Medical Center. Total bone marrow mononuclear cells were isolated by standard Ficoll procedures (GE Healthcare, Niskayuna, NY, USA) and cryopreserved in freezing medium consisting of Cryostor CS10 (BioLife Solutions, Bothell, WA, USA). The viability of leukemic cells after thawing was 50-90%. Normal bone marrow total mononuclear cells were further enriched for CD34-positive cells using MACS CD34 Enrichment Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Cell death assays
For in vitro cell death assays, normal and leukemic cells were cultured in serum-free media for 24 or 48 h in the presence of drug and analyzed with AnnexinV/7-aminoactinomycin D (7-AAD) staining using the LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). For ex vivo toxicity assays, cells were treated in vitro with rocaglamide (Enzo Life Sciences, Farmingdale, NY, USA) for 48 h, and then harvested and injected in irradiated NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. For AML and normal bone marrow specimens, engraftment of human cells was evaluated after 6-8 weeks by flow cytometry.
Colony-forming assay
A total of 5 Â 10 4 /ml of AML or normal cells were plated in Methocult GF H4534 (Stemcell Technologies, Vancouver, BC, Canada) as described previously. 17 Colonies were scored after 21 days of culture.
Methionine incorporation assay
Methionine labeling experiments and subsequent click-it chemistry were performed using reagents and protocols provided by Invitrogen/Life Sciences (Grand Island, NY, USA). Briefly, cells were grown in media lacking methionine for 1 h, incubated with Click-IT AHA (Life Technologies, Grand Island, NY, USA) for 2 h, and then washed and lysed. Click-it chemistry was performed on lysates that were subsequently run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, transferred to nitrocellulose and probed for the presence of labeled methionine with streptavidin horse radish peroxidase antibody.
Western blot
Primary antibodies for Mcl-1, Bcl-XL, Myc, phospho-p53, Bax and actin were purchased from Cell Signaling Technologies (Danvers, MA, USA). Primary antibodies for Bcl-2 and glyceraldehyde 3-phosphate dehydrogenase were purchased from Santa-Cruz Biotechnology (Dallas, TX, USA). Western blot was performed as described previously. 
Cell cycle analysis
For evaluation of the cell cycle profile, cells were fixed by the BD Fixation/ Permeabilization Kit (554714; BD Biosciences) according to the manufacturer's instructions, stained with anti-Ki67-Alexa Fluor 647 (BD Biosciences) for 45 min at 4 1C and resuspended overnight at 4 1C in 0.5 ml of 5 mg/ml 7-AAD staining solution. Cells were analyzed using BD LSRII flow cytometer (BD Biosciences).
Mitochondrial depolarization
Mitochondrial membrane depolarization was assessed using tetramethylrhodamine, ethyl ester, percholate (TMRE) purchased from Life Technologies. In vivo treatment of xenografts with silvestrol Irradiated NSG mice were transplanted with human leukemia cells (3 Â 10 6 per mouse) via tail vein in a final volume of 0.2 ml of phosphate-buffered saline with 0.5% fetal bovine serum. After 3 weeks, animals were size matched to treatment and control groups (10 animals per group) and received either silvestrol (0.75 mg/kg) or vehicle. Drugs were injected intraperitoneally for 3 weeks with a schedule of 5 days on and 2 days off (15 injections total). Silvestrol was formulated at of 0.1 mg/ml in 30% hydroxypropyl b-cyclodextrin. Following treatment, mice were killed and engrafted with human cells and were evaluated by flow cytometry.
RESULTS
Rocaglamide selectively ablates leukemia blast cells and LSCs
To establish the in vitro cytotoxicity of flavaglines, we initially treated cultures of primary human AML specimens or normal bone marrow controls with varying concentrations of rocaglamide. AML cells showed minimal cell death as measured by AnnexinV and 7-AAD at 24 h of treatment; however, toxicity increased significantly at 48 h in both total and the more primitive Figure S1D ). In agreement with xenograft experiments, in vitro colony assays showed that rocaglamide treatment resulted in only a modest reduction in normal myeloid and erythroid colony-forming units (Supplementary Figure S1E) . Taken together, these results indicate that rocaglamide is able to induce death in bulk leukemia cells, as well as in the primitive LSCs, while sparing normal stem and progenitor cells.
Rocaglamide inhibits translation, resulting in reduced levels of antiapoptotic proteins Flavaglines have previously been shown to inhibit the translation of nascent proteins. 13, 21 To verify this activity for rocaglamide, we used an epitope-tagged form of methionine and pulse-chase studies to determine and quantify inhibition of new protein synthesis. Rocaglamide markedly reduced the amount of nascent translation after 24 h treatment ( Figure 1e ). Next, we performed western blot analysis on primary AML cells treated with rocaglamide and observed reduced levels of phosphorylated 70S6K and 4EBP1, proteins critical for the initiation/regulation of cap-dependent translation (Supplementary Figure S1G) . It should be noted that the loss of phosphorylation does not appear to be the result of rocaglamide affecting mammalian target of rapamycin machinery directly; rather, it is a response to the decrease in translation caused by rocaglamide (data not shown). Taken together, these results clearly indicate that rocaglamide affects the translational status of treated cells.
Next, we examined levels of the Bcl-2 family of antiapoptotic proteins Mcl-1, Bcl-2 and Bcl-XL, some of which have been reported to decrease in other systems upon inhibition of translation. 7, 9 We observed decreases in the levels of these proteins in primary AML cells 24 h after treatment with rocaglamide ( Figure 1f) . The changes in expression levels of these proteins following rocaglamide treatment are not consistent between samples. There are clear differences in the identity of the proteins that decrease as well as in the degree of change, suggesting that the apoptosis induced by rocaglamide cannot be attributed to a decrease of one particular protein of this family, consistent with recent genetic experiments. 22 Despite the inconsistency in Bcl-2 family member reduction caused by rocaglamide treatment, in all AML specimens tested the level of at least one of the mitochondrial-associated protein decreased, leading us to further evaluate mitochondrial function. Using TMRE, a fluorescent dye indicative of mitochondrial membrane integrity, we observed that rocaglamide increased the number of cells with depolarized mitochondria (Supplementary Figure S1F) . This observation is consistent with previous studies using the closely related compound silvestrol, where LNCaP prostate cancer cells and chronic lymphocytic leukemia cells also demonstrated a loss of membrane potential. 7, 23 Overall, our results show that rocaglamide inhibits translation in AML cells, decreases the levels of antiapoptotic proteins and disrupts the mitochondrial integrity.
Rocaglamide is more cytotoxic to leukemia cells than other translational inhibitors The deregulation of translation has been implicated in cancer initiation and progression, and consequently there is significant interest in targeting this process with therapeutic agents. 24 To assess how flavaglines compare to other agents, we examined temsirolimus, a rapamycin derivative that targets the mammalian target of rapamycin pathway, and has been investigated in numerous treatment regimens for AML 25, 26 and other cancers. 27, 28 We treated the M9-ENL cell line with temsirolimus or rocaglamide for 48 h and found that rocaglamide was markedly more cytotoxic toward leukemia cells (Figure 2a ). In fact, rocaglamide was more toxic to leukemia cells than the combination of temsirolimus and ribavirin, another translational inhibitor that blocks the binding of eIF4E to the mRNA cap structure (Supplementary Figure S2A) . 26, 29 We performed methionine labeling in parallel with the cytotoxicity assays to evaluate the effect rocaglamide and temsirolimus had on the rate of translation. Strikingly, temsirolimus, which is minimally toxic to leukemia cells, inhibits global translation to a degree that is comparable to that of rocaglamide (Figure 2b ). Thus, translational inhibition alone cannot explain the relative efficacy of rocaglamide. Next, we surveyed a broad range of drugs in combination with rocaglamide to determine its potential in combination regimens. M9-ENL cells pretreated with rocagamide for 24 h before the addition of a second drug showed a strong cytotoxicity for several agents (Figure 2c ). Temsirolimus also enhanced the activity of compounds tested; however, the degree was much less than that observed with rocaglamide ( Figure 2c ). We calculated combination indices according to the Chou-Talalay method, which indicated that all combinations using rocaglamide were synergistic (Supplementary Figures S2B-E) . We also observed increased toxicity when rocaglamide was given simultaneously with the second drug; however, increases were not as large as those achieved using the pretreatment strategy (Supplementary Figure S2G ). It should be noted that not all drugs synergized with rocaglamide; in fact, the proteasome inhibitor bortezomib was antagonistic with rocaglamide, presumably because it slowed the turnover of short-lived antiapoptotic proteins (Supplementary Figure S2F) . To further explore drug synergies, we examined several combinations in primary human AML CD34 þ cell populations in vitro (Figure 2d) . Importantly, rocaglamide enhanced the cytotoxicity of cytosine arabinoside, a mainstay of AML therapeutic regimens. In addition, rocaglamide enhanced the activity of several experimental agents: (1) ABT-737, a Bcl-2 inhibitor, 30 (2) PU-H71, a new class of heat-shock protein 90 inhibitor 31 and (3) parthenolide, a potent inducer of reactive oxygen species. 32 Importantly, ABT-737 and parthenolide, like rocaglamide, show selectivity toward the LSC population as single agents, indicating that their combination holds promise for targeting more primitive leukemia cells. 18, 20 Taken together, the data indicate that rocaglamide has the potential to increase the efficacy of multiple agents, a degree of versatility that could be useful in building novel treatment regimens.
Rocaglamide modulates the activity of key transcriptional factors To better understand the mechanism of rocaglamide-mediated cell death, we performed RNA-seq-based studies to generate a comprehensive profile of gene expression changes that occur as a consequence of drug treatment. Using four primary AML specimens and the M9-ENL cell line, cells treated with or without 40 nM rocaglamide for 24 h were assayed. A total of 794 genes were differentially expressed using a Po0.05 statistical cutoff (Supplementary Table S1 ). Bioinformatic analyses of the data demonstrated that the transcription factors p53 and Myc were strongly influenced by rocaglamide treatment (Supplementary Figure S3B) . The tumor suppressor p53 is mutated in o10% of AML patients and thus its activity may be relevant to the biology of most AML cells. We observed increased phosphorylation of p53 on serine 15 following rocaglamide treatment, as well as increased levels of the proapoptotic and p53-regulated protein Bax (Figure 3a) . We speculate that increased Bax is due to enhanced protein stability, as protein synthesis is strongly inhibited by rocaglamide. To test whether p53 activation is required for rocaglamide-mediated cell death, we performed shRNA-mediated knockdown of p53 mRNA expression in M9-ENL cells and tested their sensitivity to rocaglamide. We generated three independent clones, all of which had reduced levels of p53 protein (Figure 3b ). All three clones showed resistance to rocaglamide treatment, indicating that p53 activation is a component of rocaglamide-mediated cell death (Figure 3c ). It should be noted that there is no complete rescue of cell death in our p53-deficient cells, indicating that p53 may not be the sole driver of rocaglamide-induced apoptosis. The potential for a p53-independent mechanism is consistent with experiments performed in chronic lymphocytic leukemia and LNCaP cells treated with silvestrol. 7, 23 The Myc oncogene contributes to the genesis of many human cancers and appears to have a role in LSC self-renewal. 33 We observed a strong decrease in Myc protein levels following rocaglamide treatment (Figure 3a) , consistent with our RNA-seq analysis where 485% (33 out of 38) of Myc-regulated genes were inhibited (Supplementary Figure S3A) . Importantly, the RNA-seq data and subsequent quantitative polymerase chain reaction analyses (data not shown) showed no significant decreases in Myc mRNA following rocaglamide treatment, indicating that the decreases in the level of Myc protein are the result of post-transcriptional events. Many of these downregulated genes controlled by Myc are implicated in cell cycle progression, and thus we colabeled M9 cells with anti-Ki67 and 7-AAD to evaluate cell cycle status after rocaglamide treatment. Rocaglamide decreased the percentage of actively dividing cells, while increasing the percentage of cells in G 0 (Figure 3d and Supplementary Figure S3B) . To test the importance of Myc inhibition for rocaglamide-mediated cell death, we generated M9-ENL cells in which Myc cDNA was ectopically expressed from a lentiviral promoter, which resulted in a significant increase in Myc protein levels (Figure 3e ). Despite elevated levels of Myc, rocaglamide was able to reduce Myc protein and induce apoptosis to an even greater extent than cells transduced with an empty vector (Figures 3e and f) . The increased sensitivity of the Mycexpressing cells to rocaglamide is consistent with the synthetic lethal relationship between Myc and the eIF4F complex. 34 We also tested the sensitivity of the transduced M9-ENL cells to the Myc inhibitor JQ1 and observed that, like rocaglamide, the Myc-expressing cells were more sensitive to JQ1. The similar toxicity profiles of JQ1 and rocaglamide, as well as the ability of rocaglamide to reduce the forced expression of the Myc protein, indicate that Myc inhibition is a component of the rocaglamide mechanism. Rocaglamide has a greater effect on mitochondrial integrity and Myc levels than temsirolimus To further examine the relevance of Myc reduction, we compared protein levels between rocaglamide-and temsirolimus-treated cells. Rocaglamide more effectively reduced Myc, consistent with a role for this protein in cell death (Figure 4a ). We next investigated the possibility that the mechanism of rocaglamide may extend beyond translation inhibition and that these additional activities are not shared by temsirolimus. Rocaglamide affects mitochondrial integrity (Supplementary Figure S1F) , and synergizes with the Bcl-2 inhibitor ABT-737 to a much greater degree than temsirolimus (Figure 2c) . Thus, we compared the extent of mitochondrial depolarization induced by rocaglamide and temsirolimus as single agents, as well as in combination with ABT-737. The amount of depolarization induced by rocaglamide is more than that of temsirolimus (Figure 4b and Supplementary Figure S4B) . Strikingly, the combination of rocaglamide and ABT-737 shows a significant increase in depolarization compared with ABT-737 alone or in combination with temsirolimus. In fact, the degree of depolarization is similar to levels induced by the well-characterized mitochondrial depolarizer, CCCP (Figure 4b and Supplementary  Figures S4B and C) . These results led us to further evaluate the effects rocaglamide drug combinations have on mitochondria events. Using the fluorescent dye Mitosox, which detects mitochondrial-specific superoxide, we observed significant increases in superoxide levels in cells treated with rocaglamide and ABT (Figure 4c ), but not for cells treated with either agent individually (Figure 4c) . Interestingly, the combination had no effect on reactive oxygen species as measured by the fluorescent dye CM-H2DCFDA (Supplementary Figure S4D) . CM-H2DCFDA provides a more broad measure of intracellular redox levels than Mitosox. These results indicate that the disruption of mitochondrial integrity/function is critical to the mechanism of rocaglamide. Having already established a role for p53 activation in the rocaglamide-induced cell death (Figures 3a and c) , we asked if the impaired mitochondrial function could be explained by p53 activation. Using our p53-deficient M9-ENL cells, we observed a significant reduction in mitochondrial depolarization (and increased viability, data not shown) induced by the combination of rocaglamide and ABT-737, compared with an empty vector control (Figure 4d ) This result indicates that p53 activation is critical to the mitochondrial defects induced by rocaglamide and thus its ultimate mechanism of action, and it represents properties distinct from other translational inhibitors such as temsirolimus. The flavagline compound silvestrol reduces leukemia burden in vivo Although several labs have successfully synthesized rocaglamide, [35] [36] [37] [38] [39] [40] it is still difficult to obtain rocaglamide in quantities necessary for in vivo studies. Thus, we chose to evaluate the in vivo activity of silvestrol, a closely related member of the flavagline family (Figure 5a ), which we have successfully isolated in gram quantities from the plant source. 4, 11, 41, 42 Silvestrol has previously demonstrated in vivo toxicity toward chronic lymphocytic leukemia, acute lymphoblastic leukemia and mantle cell lymphoma cells. 7, 10 We first compared the in vitro toxicity of silvestrol to rocaglamide using several primary AML samples and found that both compounds produced similar dose curves, with silvestrol showing a slight increased potency (B2-fold) (Supplementary Figure S5A) . Further, as observed for rocaglamide, silvestrol showed minimal toxicity toward normal hematopoietic cells, including primitive populations (Supplementary Figures S5B  and C) . Next, we compared the ability of silvestrol to synergize with the collection of anticancer drugs that we previously tested with rocaglamide. Similar to rocaglamide, silvestrol significantly enhanced the toxicity of all the drugs tested (Supplementary Figure S5D) . In addition to analogous cytotoxicity profiles, the molecular response induced by both compounds, including protein synthesis inhibition and a subsequent reduction in Myc protein levels, is also similar (Supplementary Figures S5E and F) . Thus, from a mechanistic standpoint, silvestrol appears to be extremely similar to rocaglamide, inducing the same molecular events and changes in cell physiology.
Next, we sought to determine the efficacy of silvestrol in reducing tumor burden in an established human-mouse xenograft. NSG mice were sublethally irradiated and injected with primary human AML cells from three independent specimens. Beginning at 3 weeks after transplant, mice were treated with 0.75 mg/kg silvestrol 5 days a week for 3 weeks, after which tumor burden, as a function of percent bone marrow engraftment, was determined (Figure 5b ). Silvestrol significantly reduced engraftment for all three specimens (Po0.05), with minimal deleterious effects on the mice as measured by viability of the marrow and weight loss during treatment (Supplementary Figure S5G) . In addition, we were able to more specifically evaluate in vivo activity of silvestrol for specimen no. 1, which had a distinct CD33 þ , CD3 þ leukemic population. As shown in Supplementary Figure  S5H , analysis of the CD33 þ /CD3 þ cells following treatment showed a preferential reduction in this aberrant clone in comparison with other cells in the graft that may represent a mixture of normal and leukemic cells. Thus, the overall decrease of CD45 þ cells may under-represent the degree of tumor reduction, which may be upwards of 10-fold (Supplementary Figure S5I) . Taken together, the data clearly indicate in vivo activity of silvestrol toward primary human AML populations.
DISCUSSION
Numerous lines of investigation have demonstrated that cellular heterogeneity for leukemia is evident at multiple levels, including immunophenotype, morphology, cell cycle status, growth potential and response to chemotherapy. 43, 44 Thus, in order for a drug to provide durable remissions, it must be capable of targeting multiple cell types, each having distinct properties. Furthermore, drugs that target LSC, while sparing normal HSC, are of particular interest. Results presented here indicate that drugs of the flavagline class (rocaglamide and silvestrol) represent promising candidates for the development of improved AML regimens. They are toxic to total AML cells, as well as AML stem cells, as assayed by engraftment of NSG mice, whereas normal hematopoietic cells, including HSCs, are largely unaffected under the same conditions. Further, in vivo experiments show that silvestrol is able to reduce the tumor burden of mice engrafted with primary AML cells, with minimal deleterious effects on the mice.
In comparison with temsirolimus, rocaglamide and silvestrol are significantly more toxic to leukemia cells when given as single agents or in combination with other drugs. Interestingly, this increased cytotoxicity does not directly correlate with the ability of the compounds to inhibit translation as temsirolimus inhibits translation at levels equal to or greater than rocaglamide. This observation led us to further investigate the molecular mechanism of cell death induced by rocaglamide. Using several assays, we showed that rocaglamide leads to p53 activation, Myc reduction, cell cycle inhibition and defects in mitochondrial integrity. Each of these activities appears to contribute to the overall activity of rocaglamide.
The observation that rocaglamide and temsirolimus inhibit global protein synthesis to a similar extent does not eliminate the possibility that the compounds differentially affect the translation rates of a subset of proteins critical for the survival of leukemia cells. We looked at Myc levels following drug treatment and observed a striking difference in the level of reduction following treatment with rocaglamide, as compared with temsirolimus. An inability to reduce Myc levels has been reported for other mammalian target of rapamycin inhibitors in AML cells and may represent a limitation to this class of compounds for treating AML. 17 The importance of Myc activity in the biogenesis and progression of cancer has long been appreciated; however, up until recently; the ability to target Myc remained elusive. [45] [46] [47] Silvestrol, JQ1 and other BET bromodomain inhibitors currently in development present viable therapeutic options for targeting this nexus.
In addition to their potency as single agents, we also show that rocaglamide and silvestrol increase the cytotoxicity of several types of drugs toward AML cells, including daunorubicin and cytosine arabinoside, two chemotherapeutic drugs currently used to treat AML patients. The broad range of drug classes that, rocaglamide and silvestrol, are able to enhance is quite striking. It is possible that these compounds are blocking translation-based survival mechanisms induced by the second drug; however, one would expect all translational inhibitors to synergize with these compounds, which is not the case (Figure 2c ). We propose that the ability of rocaglamide to synergize is related, at least in part, to the effect it has on mitochondrial integrity/function (Figure 4b ). The mitochondrial defect induced by rocaglamide treatment in essence 'primes' cells for death when the second drug hits. Using M9-ENL cells harboring shRNA constructs targeting p53, we were able link the mitochondrial defects with p53 activation (Figure 4d) , indicating a critical role for this node in the mechanism of action of flavaglines.
The deregulation of translation is a critical feature of cancer initiation and progression, and thus there is great interest in targeting protein synthesis therapeutically. 48, 49 Data presented here and in other labs have shown that targeting the translational initiation complex with flavaglines can be preferentially toxic to transformed cells. 50, 51 Silvestrol is the first direct inhibitor of translation initiation with clinical potential. It is now under development at the National Cancer Institute's NExT Program, with current efforts dedicated to toxicology and scale-up using supercritical fluid extraction. Adequate raw materials for preclinical toxicology studies have already been collected by the source country, and Ohio State University has received an exclusive license to develop silvestrol for the treatment of Primary AML cells were injected into sublethally irradiated mice. Three weeks after transplant, mice were either treated with silvestrol or vehicle for 3 weeks. For AML nos. 1 and 2, silvestrol was administered at 0.75 mg/kg daily, five times a week for 3 weeks. Silvestrol was administered three times a week for 3 weeks at a dose of 1.5 mg/kg for mouse engrafted with AML no. 3. Mice were killed and the bone marrow was analyzed for the percentage of human cells using anti-human CD45 antibody.
cancer. We believe that the therapeutic flexibility, in vivo efficacy and ability to target LSCs pose intriguing possibilities for these compounds to serve as adjuvants to current therapeutic regimes.
